Accès ouvert

Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease

Article scientifique 2023 Anglais

Résumé

Gallium-68 fibroblast activation protein inhibitor [(68Ga)Ga-FAPI] is a new radiopharmaceutical positioning itself as the preferred agent in patients with malignant tumours, competing with 2-Deoxy-2-[18F]fluoro-d-glucose [2-(18F)FDG] using positron emission tomography (PET). While imaging oncology patients with [68Ga]Ga-FAPI PET, incidental uptake of [68Ga]Ga-FAPI has been detected in the myocardium. This review summarises original research studies associating the visualisation of FAPI-based tracers in the myocardium with underlying active cardiovascular disease.

Citer ce document

Mpanya, D., Sathekge, M., Klug, E., Damelin, J., More, S., Hadebe, B., Vorster, M., Tsabedze, N. (2023). Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease. https://doi.org/10.3389/fnume.2023.1224905

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Auteur(s)

Dineo Mpanya Mike Sathekge E Klug Jenna Damelin Stuart More Bawinile Hadebe Mariza Vorster Nqoba Tsabedze

Statistiques

Consultations : 1

Téléchargements : 0